drug.trial_access for nintedanib

The record

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "NINTEDANIB",
 "recruitingInterventionalCount": 9,
 "notYetRecruitingCount": 6,
 "byPhase": {
  "PHASE2": 4,
  "PHASE1": 1,
  "PHASE3": 3,
  "PHASE1/PHASE2": 1
 },
 "trials": [
  {
   "nctId": "NCT07194382",
   "briefTitle": "AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Avalyn Pharma Inc.",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-15",
   "startDate": "2026-03-10",
   "conditions": [
    "Idiopathic Pulmonary Fibrosis (IPF)"
   ],
   "countries": [
    "Australia",
    "Canada",
    "Germany",
    "New Zealand",
    "Spain",
    "Turkey (Türkiye)",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07194382"
  },
  {
   "nctId": "NCT07679893",
   "briefTitle": "Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Mannkind Corporation",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-09-14",
   "startDate": "2026-05-15",
   "conditions": [
    "Idiopathic Pulmonary Fibrosis",
    "Idiopathic Pulmonary Fibrosis (IPF)"
   ],
   "countries": [
    "Canada"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07679893"
  },
  {
   "nctId": "NCT07454291",
   "briefTitle": "A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants",
   "phase": [
    "PHASE1"
   ],
   "leadSponsor": "Endeavor Biomedicines, Inc.",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-05-15",
   "startDate": "2026-04-28",
   "conditions": [
    "Idiopathic Pulmonary Fibrosis"
   ],
   "countries": [
    "Australia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07454291"
  },
  {
   "nctId": "NCT06297096",
   "briefTitle": "Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-04-08",
   "startDate": "2025-07-01",
   "conditions": [
    "Systemic Sclerosis",
    "Interstitial Lung Disease"
   ],
   "countries": [
    "Poland"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06297096"
  },
  {
   "nctId": "NCT07299695",
   "briefTitle": "Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Argyrios Tzouvelekis",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-03-16",
   "startDate": "2026-01-25",
   "conditions": [
    "Idiopathic Pulmonary Fibrosis",
    "Acute Exacerbation of Idiopathic Pulmonary Fibrosis"
   ],
   "countries": [
    "Greece"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07299695"
  },
  {
   "nctId": "NCT04976036",
   "briefTitle": "Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Dr. Romain Lazor",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-03-11",
   "startDate": "2022-05-05",
   "conditions": [
    "Telangiectasia, Hereditary Hemorrhagic"
   ],
   "countries": [
    "France",
    "Switzerland"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04976036"
  },
  {
   "nctId": "NCT05674994",
   "briefTitle": "Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Fondation Hôpital Saint-Joseph",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-03-02",
   "startDate": "2023-10-26",
   "conditions": [
    "Acute Exacerbation of Idiopathic Pulmonary Fibrosis"
   ],
   "countries": [
    "France"
   ],
   "url": "https://clinicaltrials.gov/study/NCT05674994"
  },
  {
   "nctId": "NCT06742502",
   "briefTitle": "Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Sun Yat-sen University",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2025-06-05",
   "startDate": "2024-11-12",
   "conditions": [
    "Primary Mediastinal Diffuse Large B-cell Lymphoma"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06742502"
  },
  {
   "nctId": "NCT06071013",
   "briefTitle": "Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "China Medical University Hospital",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2025-01-23",
   "startDate": "2024-02-23",
   "conditions": [
    "Non-small Cell Lung Cancer",
    "EGFR Gene Mutation",
    "EGFR-TKI Resistant Mutation"
   ],
   "countries": [
    "Taiwan"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06071013"
  }
 ],
 "query": {
  "intr": "nintedanib",
  "filterOverallStatus": "RECRUITING",
  "filterAdvanced": "AREA[StudyType]INTERVENTIONAL",
  "sort": "LastUpdatePostDate:desc",
  "apiVersion": "2.0.5"
 },
 "attribution": "ClinicalTrials.gov",
 "dataProcessedByRegistry": "2026-11-06T10:00:05",
 "modifications": "Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited."
}

SHA-256 of the exact stored value: 88cce355b8705fe8d16963754b7b2e859e5b6e0d5ca0b04d505c8a36484c0db0.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.